Peter Edward Fecci

Peter Edward Fecci
Assistant Professor of Neurosurgery
Third Year Mentor - Molmed - Molecular Basis of Disease Study Track
Third Year Mentor - Neurosciences Study Program (NSS)
Campus mail: 201 Sands Bldg., Box 3050, Durham, NC 27710
Phone: (919) 681-1010

Education and Training

  • Duke University School of Medicine, M.D. 2007
  • Duke University, Ph.D. 2007
  • Massachusetts General Hospital, Internship, General Surgery
  • Massachusetts General Hospital, Residency, Neurosurgery
  • Dana Farber Cancer Institute, Postdoctoral Fellow
  • Massachusetts General Hospital, Instructor, Neurosurgery


Prospect of rindopepimut in the treatment of glioblastoma.

Rindopepimut (CDX-110) is a peptide vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific epitope expressed in the most common and lethal primary malignant neoplasm of the brain - glioblastoma (GBM).

Regulatory T cells move in when gliomas say "I Do".

Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression.